Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;19(1):12-21.
doi: 10.1093/neuonc/now190. Epub 2016 Sep 20.

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

Affiliations
Review

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

Edward K Avila et al. Neuro Oncol. 2017 Jan.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Neuro Oncol. 2017 Feb 1;19(2):304. doi: 10.1093/neuonc/nox015. Neuro Oncol. 2017. PMID: 28391302 Free PMC article. No abstract available.

Abstract

Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment trials is proposed.

Keywords: glioma; low-grade; metric; scale; seizures.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Proposed seizure assessment tool

Comment in

Similar articles

Cited by

References

    1. Taphoorn MJ. Neurocognitive sequelae in the treatment of low-grade gliomas. Semin Oncol. 2003;30(Suppl):45–48. - PubMed
    1. Stockhammer F, Misch M, Helms HJ. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. 2012;21(3):194–197. - PubMed
    1. van den Bent MJ, Wefel JS, Schiff D. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583–593. - PubMed
    1. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30(4):389–399. - PubMed
    1. Cascino GD. Epilepsy and brain tumors: implications for treatment. Epilepsia. 1990;31(Suppl 3):S37–44. - PubMed

Publication types